The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.75
Bid: 17.42
Ask: 18.08
Change: 0.00 (0.00%)
Spread: 0.66 (3.789%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 17.75
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Licence Partner Update

25 Mar 2020 17:05

RNS Number : 6248H
Nanoco Group PLC
25 March 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

 

FOR IMMEDIATE RELEASE

 25 March 2020

NANOCO GROUP PLC

("Nanoco", the "Group", or the "Company")

 

Licence Partner Update

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from our technology platform, announces the following update on its licence agreement with Merck Gmbh ("Merck").

Merck have indicated their intention to negotiate a new supply and licensing agreement to replace the existing one which was signed on 29 July 2016. That licence was an evergreen agreement that renewed automatically every year and had escalating minimum annual royalties that were payable unless terminated. Merck have chosen to issue a three month notice of termination of the existing licence while renegotiations take place. Merck and Nanoco continue to work closely to find a mutually acceptable agreement.

During this time Merck continue to place additional purchase orders with Nanoco for small scale R&D services and CFQD product for display applications while the renegotiation takes place. The minimum annual licence fee of 0.5m for the contract year ending 30 June 2020 will still be payable and no previously forecast income or cash has been lost as a result of this decision by Merck.

The Company is continuing to review its strategic options including, but not limited to, a potential sale of the Company through a formal sale process as announced on 5 November and will make a further announcement in due course.

 

Michael Edelman, Chief Executive of Nanoco, said:

"We continue to work collaboratively with Merck and we had based our plans and forecasts on the risk of this renegotiation occurring. While we continue to actively engage with Merck to find a new basis for long term co-operation we will continue to supply them with paid for R&D services and CFQD product."

- Ends -

 

For further information, please contact:

 

Nanoco

Tel: +44 (0) 161 603 7900

Brian Tenner, Chief Financial Officer

Caroline Watson, Investor Relations Manager

Tel: + 44 (0) 7799 897357

cwatson@nanocotechnologies.com

MHP Communications

Reg Hoare / Giles Robinson / Pete Lambie

nanoco@mhpc.com

Tel: +44 (0) 20 3128 8570

 

In accordance with Rule 26.1 of the City Code on Takeovers and Mergers, a copy of this announcement will, subject to certain restrictions relating to persons resident in restricted jurisdictions, be available at www.nanocotechnologies.com/investor-relations/. The person responsible for arranging for the release of this announcement on behalf of Nanoco is Brian Tenner, Chief Financial Officer. For the avoidance of doubt, the content of the website referred to above is not incorporated into and does not form part of this announcement.

 

This announcement is not an announcement of a firm intention to make an offer under Rule 2.7 of the Code and there can be no certainty that an offer will be made, nor as to the terms on which any offer might be made. Any offer (if made) will be made solely by certain offer documentation, which will contain the full terms and conditions of any offer (if made), including details of how such offer may be accepted. This announcement has been prepared in accordance with English law and the Code, and information disclosed may not be the same as that which would have been prepared in accordance with laws outside of the United Kingdom. The release, distribution or publication of this announcement in jurisdictions outside of the United Kingdom may be restricted by laws of the relevant jurisdictions, and therefore persons into whose possession this announcement comes should inform themselves about, and observe, any such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.

 

MAR

 

The information contained within this announcement is considered by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information will be considered to be in the public domain.

 

FORWARD LOOKING STATEMENTS

 

This announcement (including information incorporated by reference in this announcement), oral statements made regarding the formal sale process, and other information published by Nanoco may contain statements about Nanoco that are or may be deemed to be forward looking statements. Such statements are prospective in nature. All statements other than historical statements of facts may be forward looking statements. Without limitation, statements containing the words "targets", "plans", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "estimates", "projects" or "considers" or other similar words may be forward looking statements.

 

Forward looking statements inherently contain risks and uncertainties as they relate to events or circumstances in the future. Important factors such as business or economic cycles, the terms and conditions of Nanoco's financing arrangements, tax rates, or increased competition may cause Nanoco's actual financial results, performance or achievements to differ materially from any forward looking statements. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward looking statements, which speak only as of the date hereof. Nanoco disclaims any obligation to update any forward looking or other statements contained herein, except as required by applicable law.

 

Notes for editors:

 

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display and Electronics markets. One of the interesting properties of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco has non-exclusive manufacturing and marketing licensing agreements in display with The Dow Chemical Company, Merck KGaA of Germany and Wah Hong Industrial Corporation of Taiwan.Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDEAXDSAEFEEFA
Date   Source Headline
30th Jul 20157:01 amRNSProgress Update
1st Jul 20157:00 amRNSCommissioning of Cheonan Plant
24th Jun 20157:00 amRNSNotification of Major Interest in Shares
19th Jun 20157:00 amRNSNotification of Major Interest in Shares
11th Jun 20151:45 pmRNSNotification of Major Interest in Shares
8th Jun 20151:00 pmRNSNotification of Major Interest in Shares
4th Jun 20154:15 pmRNSBlocklisting Application
28th May 20157:00 amRNSAppointment of Non-Executive Director
26th May 20152:15 pmRNSNotification of Major Interest in Shares
20th May 20152:31 pmRNSWelcomes MEPs' Rejection of Cadmium Quantum Dots
7th May 20157:00 amRNSAppointment of Chief Financial Officer
5th May 20155:00 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
5th May 201512:15 pmRNSNotification of Major Interest in Shares
1st May 20154:00 pmRNSNotification of Major Interest in Shares
1st May 20154:00 pmRNSHolding(s) in Company
1st May 20158:00 amRNSFirst Day of Dealings on the Main Market
28th Apr 20155:00 pmRNSNotification of Major Interest in Shares
28th Apr 201510:00 amRNSNotification of Major Interest in Shares
28th Apr 20159:30 amRNSNotification of Major Interest in Shares
27th Apr 20159:30 amRNSNotification of Major Interest in Shares
24th Apr 201512:00 pmRNSNotification of Major Interest in Shares
22nd Apr 20155:29 pmRNSNotification of Major Interest in Shares
22nd Apr 20154:45 pmRNSResult of GM, Move to Main Market and Placing
21st Apr 20158:00 amRNSNotification of Major Interest in Shares
21st Apr 20158:00 amRNSNotification of Major Interest in Shares
14th Apr 20157:00 amRNSInnovate UK Grant Award
13th Apr 20157:00 amRNSNotification of Major Interest in Shares
9th Apr 20154:45 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
8th Apr 20158:00 amRNSNotification of Major Interest in Shares
31st Mar 20155:00 pmRNSPublication of Prospectus and Posting of Circular
30th Mar 20154:35 pmRNSPrice Monitoring Extension
24th Mar 20159:15 amRNSNotification of Major Interest in Shares
23rd Mar 20157:00 amRNSInterim Results
17th Mar 20153:30 pmRNSPresentation at the Quantum Dots Forum 2015
4th Mar 20157:00 amRNSNotification of Major Interest in Shares
4th Mar 20157:00 amRNSNotification of Interim Results
25th Feb 20157:02 amRNSNotification of Major Interest in Shares
13th Feb 20158:00 amRNSNotification of Major Interest in Shares
11th Feb 20158:00 amRNSNotification of Major Interest in Shares
6th Feb 20155:23 pmRNSNotification of Major Interest in Shares
5th Feb 20157:00 amRNSNotification of Major Interest in Shares
2nd Feb 20157:00 amRNSRoHS Update
20th Jan 20154:44 pmRNSNotification of Major Interest in Shares
9th Jan 20157:00 amRNSLG Electronics Partners with Dow
8th Jan 20158:30 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Jan 20157:00 amRNSNotification of Major Interest in Shares
5th Jan 20157:00 amRNSNotification of Major Interest in Shares
2nd Jan 20157:00 amRNSDirectorate Change
30th Dec 20147:00 amRNSSigns Manufacturing Contract with Dow
23rd Dec 20147:00 amRNSNotification of major interest in shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.